The Experts below are selected from a list of 244650 Experts worldwide ranked by ideXlab platform
Tanja D. Gruijl - One of the best experts on this subject based on the ideXlab platform.
-
Unlocking the therapeutic potential of Primary Tumor-draining lymph nodes
Cancer Immunology Immunotherapy, 2019Co-Authors: Jossie Rotman, Bas D. Koster, Ekaterina S. Jordanova, A. Marijne Heeren, Tanja D. GruijlAbstract:Lymph nodes draining the Primary Tumor are essential for the initiation of an effective anti-Tumor T-cell immune response. However, cancer-derived immune suppressive factors render the Tumor-draining lymph nodes (TDLN) immune compromised, enabling Tumors to invade and metastasize. Unraveling the different mechanisms underlying this immune escape will inform therapeutic intervention strategies to halt Tumor spread in early clinical stages. Here, we review our findings from translational studies in melanoma, breast, and cervical cancer and discuss clinical opportunities for local immune modulation of TDLN in each of these indications.
Alex G Little - One of the best experts on this subject based on the ideXlab platform.
-
metastatic squamous cell carcinoma of the mediastinum with unknown Primary Tumor
Chest, 1998Co-Authors: Neri Blanco, Daniel M Kirgan, Alex G LittleAbstract:Although metastatic carcinoma from an unknown Primary Tumor is known to occur, the combination of squamous cell carcinoma histologic findings and a mediastinal location is quite unusual. The evaluation of a case of a patient with a posterior mediastinal mass, eventually shown to be metastatic squamous cell carcinoma of the mediastinum with unknown Primary Tumor, is described herein. Resection of the lymph node mass was performed and was followed by chemoradiation for presumed lung cancer. (CHEST 1998; 114:938–940)
Mu-kuan Chen - One of the best experts on this subject based on the ideXlab platform.
-
Primary Tumor volume measured by FDG PET and CT in nasopharyngeal carcinoma.
Clinical nuclear medicine, 2011Co-Authors: Guang-uei Hung, Hong-shen Lee, Weir-chiang You, Hui-chuan Chen, Mu-kuan ChenAbstract:Background:The prognostic value of CT-derived Primary Tumor volume in patients with nasopharyngeal carcinoma (NPC) has been demonstrated in our previous serial studies. The purpose of the present study is to compare the Primary Tumor volume measured by FDG PET and traditional CT in NPC, and to ascer
-
Primary Tumor Volume Is an Independent Predictor of Outcome Within pT4a-Staged Tongue Carcinoma
Annals of surgical oncology, 2010Co-Authors: Mu-kuan Chen, Chih Ming Chen, Ming Che Lee, Li Sheng Chen, Hui-chuan ChenAbstract:Background We evaluated the heterogeneity of Primary Tumor volume (PTV) within Tumors of the same pT4a-staged tongue carcinoma and to elucidate the effects of PTV on treatment outcomes in patients with pT4a-staged tongue carcinoma.
-
Better prediction of prognosis for patients with nasopharyngeal carcinoma using Primary Tumor volume.
Cancer, 2004Co-Authors: Mu-kuan Chen, Tony Hsiu-hsi Chen, Jen-pei Liu, Cheng-chuan Chang, Wei-chu ChieAbstract:BACKGROUND. Heterogeneity of Primary Tumor volume within Tumors of the same classification indicates a need to elucidate the effects of Primary Tumor volume on treatment outcomes in patients with nasopharyngeal carcinoma (NPC). METHODS. From 1994 through 1996, 129 patients with newly diagnosed NPC who were treated with high-dose radiotherapy were enrolled in the study. Computed tomography-derived Primary Tumor volume was measured using the summationof-area technique. Correlations between American Joint Committee on Cancer (AJCC) disease stage, Primary Tumor volume, and disease-specific survival were assessed using a Cox regression model. Cross-validation based on receiver operating characteristic (ROC) curve also was examined. RESULTS. Compared with the AJCC staging system and the TNM classification system, Primary Tumor volume was better at determining cumulative survival for patients with NPC. Hazard ratios increased with Tumor volume, ranging from 6.68 (95% confidence interval [95% CI], 1.89 –23.67) for Tumor volumes between 20 – 40 mL, 18.03 (95% CI, 4.80 – 67.75) for Tumor volumes between 40 – 60 mL, and 26.06 (95% CI, 7.70 – 88.20) for Tumor volumes 60 mL. With both Tumor volume and T classification in the same Cox regression model, only Tumor volume remained statistically significant in the prognosis of NPC. The validation results with ROC curves also revealed that, in predicting patient outcome, Primary Tumor volume (area under the ROC 83.33%) was superior to disease stage (area under the ROC 66.53%) and TNM classification (area under the ROC 58.61%). CONCLUSIONS. The incorporation of Primary Tumor volume may lead to a further refinement of the current AJCC staging system, particularly for patients with large Primary Tumor volumes ( 60 mL), who require more aggressive treatment. Cancer 2004;100:2160 – 6. © 2004 American Cancer Society.
-
The effect of Primary Tumor volumes in advanced T‐staged nasopharyngeal Tumors
Head & neck, 2002Co-Authors: Cheng-chuan Chang, Mu-kuan Chen, Mu-tai LiuAbstract:Background Tumor volume is an important prognostic factor in patients with malignancy treated with Primary radiotherapy. It is necessary to have a clear understanding of the nasopharyngeal Primary Tumor volume and the treatment outcome, especially in the advanced T-staged Tumors. Methods From 1994–1996, 76 newly diagnosed patients with advanced T-staged nasopharyngeal carcinomas who were treated with high-dose radiotherapy with or without chemotherapy were included in this study. CT-derived Primary Tumor volume was obtained after the summation of area technique. Results The median Primary Tumor volume was 29.6 mL in T3 disease and 54.1 mL in T4 disease, with a range of 8.0–131.8 in T3 disease, and 6.7–223.1 ml in T4 disease. Large Primary Tumor volume was associated with a significantly poor disease-specific survival (p < .0001), whereas the T stage carried no prognostic significance (p = .43). Conclusions In advanced T-staged (T3 and T4) nasopharyngeal Tumors, a substantial variation of Primary Tumor volume was present within the same T stage, and Primary Tumor volume represented a more important prognostic factor for treatment outcome. Volumetric measurements of Primary Tumors in advanced nasopharyngeal Tumors would refine the TNM staging system. Patients with large Primary Tumor volume should be treated more aggressively. © 2002 Wiley Periodicals, Inc. Head Neck 24: 940–946, 2002
Jossie Rotman - One of the best experts on this subject based on the ideXlab platform.
-
Unlocking the therapeutic potential of Primary Tumor-draining lymph nodes
Cancer Immunology Immunotherapy, 2019Co-Authors: Jossie Rotman, Bas D. Koster, Ekaterina S. Jordanova, A. Marijne Heeren, Tanja D. GruijlAbstract:Lymph nodes draining the Primary Tumor are essential for the initiation of an effective anti-Tumor T-cell immune response. However, cancer-derived immune suppressive factors render the Tumor-draining lymph nodes (TDLN) immune compromised, enabling Tumors to invade and metastasize. Unraveling the different mechanisms underlying this immune escape will inform therapeutic intervention strategies to halt Tumor spread in early clinical stages. Here, we review our findings from translational studies in melanoma, breast, and cervical cancer and discuss clinical opportunities for local immune modulation of TDLN in each of these indications.
Jun Wang - One of the best experts on this subject based on the ideXlab platform.
-
Enhanced Primary Tumor Penetration Facilitates Nanoparticle Draining into Lymph Nodes after Systemic Injection for Tumor Metastasis Inhibition
ACS nano, 2019Co-Authors: Jing Liu, Ying-li Luo, Jun WangAbstract:Lymph nodes (LNs) are normally the Primary site of Tumor metastasis, and effective delivery of chemotherapeutics into LNs through systemic administration is critical for metastatic cancer treatment. Here, we uncovered that improved perfusion in a Primary Tumor facilitates nanoparticle translocation to LNs for inhibiting Tumor metastasis. On the basis of our finding that an iCluster platform, which undergoes size reduction from ∼100 nm to ∼5 nm at the Tumor site, markedly improved particle perfusion in the interstitium of the Primary Tumor, we further revealed in the current study that such Tumor-specific size transition promoted particle intravasation into Tumor lymphatics and migration into LNs. Quantitative analysis indicated that the drug deposition in LNs after iCluster treatment was significantly higher in the presence of a Primary Tumor in comparison with that after Primary Tumor resection. Early intervention of metastatic 4T1 Tumors with iCluster chemotherapy and subsequent surgical resection of the Primary Tumor resulted in significantly extending animal survival, with 4 out of the 10 mice remaining completely Tumor-free for 110 days. Additionally, in the more clinical relevant late metastatic model, iCluster inhibited the metastatic colonies to the lungs and extended animal survival time. This finding provides insights into the design of more effective nanomedicines for treating metastatic cancer.
